The Effectiveness of the Varicella Vaccine in Clinical Practice
- 29 March 2001
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 344 (13), 955-960
- https://doi.org/10.1056/nejm200103293441302
Abstract
A live attenuated varicella vaccine was approved for use in the United States in March 1995 and is recommended for all susceptible persons 12 months of age or older.Keywords
This publication has 13 references indexed in Scilit:
- Varicella Outbreaks After Vaccine Licensure: Should They Make You Chicken?PEDIATRICS, 1999
- Postlicensure effectiveness of varicella vaccine during an outbreak in a child care centerJAMA, 1997
- Varicella Vaccine: The Japanese ExperienceThe Journal of Infectious Diseases, 1996
- Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescentsThe Pediatric Infectious Disease Journal, 1995
- Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studiesVaccine, 1991
- Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessmentJAMA, 1985
- Resolving the Pneumococcal Vaccine Controversy: Are There Alternatives to Randomized Clinical Trials?Clinical Infectious Diseases, 1984
- Live attenuated varicella vaccine. Efficacy for children with leukemia in remissionJAMA, 1984
- Live Attenuated Varicella Virus VaccineThe New England Journal of Medicine, 1984
- LIVE VACCINE USED TO PREVENT THE SPREAD OF VARICELLA IN CHILDREN IN HOSPITALThe Lancet, 1974